cliniMACs HUD for T Cell Depletion

• Conditions: x Linked Combined Immunodeficiency

• Registration Number: NCT02915406
• Lead Sponsor: University of Miami

Brief Summary

This protocol is designed to enable access to related or unrelated CD34 cells manufactured using the CliniMACS (Miltenyi) under the HUD designation for patients needing T cell depleted allogeneic grafts for hematopoietic stem cell transplant (HSCT). This will include patients with inherited immunodeficiency disorders as well as patients with malignancies, bone marrow failure, and other rare diseases amenable to HSCT. Finally, patients with poor graft function and Graft Versus Host Disease(GVHD) after a previous HSCT may require a boost of T-cell depleted donor Peripheral Blood Stem Cell (PBSCs) or bone marrow cells that are CD34 selected using the CliniMACS device ENROLLMENT BY INVITATION ONLY

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2016-09-23
• Study First Submitted QC: 2016-09-23
• Study First Posted: 2016-09-27
• Status Verified: 2017-08
• Last Update Submitted: 2017-08-12
• Last Update Posted: 2017-08-16

Recruitment & Eligibility

• Status: NO_LONGER_AVAILABLE
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

severe combined immune deficiency need for stem cell boost

Read More

Exclusion Criteria

n/a

Read More

Study & Design

• Study Type: EXPANDED_ACCESS
• Study Design: Not specified

Trial Locations

Locations (1)

University of Miami; 🇺🇸 Miami, Florida, United States